Publication
PlasmaCap EBA: An innovative method of isolating plasma proteins from human plasma (online link)
Publication
Press Release
September 6, 2022 Mississauga, ON, Canada – Evolve Biologics Inc. (“Evolve”), an innovative plasma-derived therapeutics company, is pleased to announce the appointment of Chris Carr as Chief Financial Officer. Chris will be responsible for all finance and accounting functions at Evolve and as a senior member of the executive team, Chris will be reporting to CEO Jim Caggiano.
Press Release
03 Dec, 2021 – Mississauga, ON, Canada (December 6, 2021) – Evolve Biologics Inc. (“Evolve”), an innovative plasma-derived therapeutics company, today announced the site selection, land purchase and groundbreaking ceremony for its first manufacturing facility in Sachse, Texas. This state-of-the-art facility will be the first to use Evolve’s innovative and proprietary technology, PlasmaCap EBA®, to commercially produce plasma-derived therapeutics, initially Intravenous Immunoglobulin (IVIG) and Human Serum Albumin (HSA).
Publication
22nd Oct 2021 – Las Vegas, NV (October 22nd, 2021) – Evolve presented updated results on behalf of Dr Richard Wasserman from the completed PlasmaCap IG Phase III Clinical Trial entitled “Efficacy and Safety of PlasmaCap IG, a New 10% Intravenous Immunoglobulin Manufactured Using an Innovative Chromatography Process, In Adults and Children with Primary Immunodeficiency Disorders”
Press Release
Evolve’s manufacturing facility to be located in Texas and first globally to use PlasmaCap EBA® technology in commercial-scale production of plasma-derived therapeutics Innovative technology extracts plasma proteins more efficiently and at higher yields to improve the long-term reliable supply of critical plasma-derived therapeutics Mississauga, ON, Canada (May 17, 2021) – Evolve Biologics Inc. (“Evolve”), an innovative plasma-derived […]
Publication
16 Apr, 2021 – Virtual Meeting (April 16, 2021) – Dr Richard Wasserman presented results from the completed PlasmaCap IG Phase III Clinical Trial entitled “Efficacy and Safety of PlasmaCap IG, a New 10% Intravenous Immunoglobulin Manufactured Using an Innovative Chromatography Process, In Adults and Children with Primary Immunodeficiency Disorders”. Abstracts available here
Press Release
10 Mar, 2021 – Mississauga, ON, Canada (March 10, 2021) – Evolve Biologics Inc. (“Evolve”), an innovative plasma-derived therapeutics company, today provided an update on its continued progress toward the development and commercialization of its PlasmaCap EBA technology and its strong position as an innovative developer and manufacturer of these critical products.
Press Release
09 Feb, 2021 – Mississauga, ON, Canada (February 9, 2021) – Evolve Biologics Inc. (“Evolve”), an innovative plasma-derived therapeutics company, today announced that it has successfully completed its adult and pediatric Phase III clinical trial of PlasmaCap IG (Intravenous Immunoglobulin or “IVIG”), conducted at 12 study centers across the U.S. and Canada. PlasmaCap IG is an investigational IVIG replacement therapy for adult and pediatric patients with primary immune deficiency disease (“PIDD”).
Press Release
19 Jan, 2021 – Mississauga, ON, Canada (January 19, 2021) – Evolve Biologics Inc. (“Evolve”), an innovative plasma-derived therapeutics company, today announced the appointment of Jim Caggiano as CEO. Mr. Caggiano’s nearly 30 years of experience, bringing life-saving products to the market in the biotech, pharma and medical device industries, will help accelerate commercialization of the company’s PlasmaCap EBA technology, which stands to disrupt the global plasma-derived therapeutics market with its high-quality product yields at improved levels of efficiency and reliability compared to currently available technologies. Mr. Caggiano joins the company’s proven leadership team of David Holliday, Chief Commercial Officer, and Mark Krause, Head of Plasma Proteins.
Publication
25 Oct, 2019 – Las Vegas, NV (October 25, 2019) – Evolve presented “Interim results of a novel 10% liquid intravenous immune globulin (IVIG) product’s Phase III Prospective, Open-Label Multicenter Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics in Adults and Children with Primary Immunodeficiency Disease (PIDD)”. Abstracts available here.
Publication
24 Feb, 2019 – San Francisco, CA (February 24, 2019) – Dr Richard Wasserman presented “Interim Safety Data in a Prospective, Open-Label, Multi-Center Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of PlasmaCap IG in Patients with Primary Immunodeficiency Diseases (PIDDs)”. Abstract published in Journal of Allergy Clinical Immunology (JACI).
Publication
19 Oct, 2018 – Dallas, TX (October 19, 2018) – Evolve presented “A prospective, open-label, multicenter study of the efficacy, safety, tolerability, and pharmacokinetics of PlasmaCapTM IG (Immunoglobulin) in adults and children with primary immunodeficiency” and “PlasmaCap EBA™, an innovative method of isolating plasma proteins from human plasma”. Abstracts available here.
Press Release
25 Sep, 2018 – Mississauga, ON, Canada (September 25, 2018) – Evolve Biologics (“Evolve”), a division of Therapure Biopharma Inc. (“Therapure”) and an innovative developer of plasma-derived therapeutics, today provided an update on continued progress in its Phase III multicenter clinical trial of PlasmaCap™ IG (Intravenous Immunoglobulin or “IVIG”), an investigational IVIG replacement therapy being studied in both adult and pediatric patients with primary immune deficiency diseases (“PIDD”).
Press Release
04 May, 2018 – Mississauga, ON, Canada (May 4, 2018) – Evolve Biologics (“Evolve”), a division of Therapure Biopharma Inc. (“Therapure”) and an innovative developer of plasma-derived therapeutics, today announced that it has dosed the first pediatric patient in its Phase III multicenter clinical trial of PlasmaCap™ IG (Intravenous Immunoglobulin or “IVIG”), in addition to having administered half of the infusions required for the adult portion of the study, which completed enrollment in February 2018.
Press Release
28 Mar, 2018 – Mississauga, ON, Canada – March 28, 2018 – Evolve Biologics, the biologics division of Therapure Biopharma Inc., today announced that in February 2018 the company confidentially submitted a draft registration statement on Form F-1 with the U.S. Securities and Exchange Commission (the “SEC”) relating to the proposed initial public offering of its common shares. The initial public offering is expected to commence after the SEC completes its review process, subject to market and other conditions.
Press Release
23 Mar, 2018 – Mississauga, ON, Canada (March 23, 2018) – Therapure Biopharma Inc. (“Therapure”) today announced it has launched its plasma products and technology division as Evolve Biologics (“Evolve”), an innovative developer of plasma-derived therapeutics, led by an experienced senior management team. Evolve’s leadership team consists of Chief Executive Officer Blaine Forshage; Chief Commercial Officer, David Holliday; and Chief Financial Officer, Gregory Gould. All three industry veterans bring significant experience in the global plasma-derived therapeutics market.